Identification of reliable molecular markers that show differential expression between distinct groups of samples has remained a fundamental research problem in many large-scale profiling studies, such as those based on DNA microarray or mass-spectrometry technologies. Despite the availability of a wide spectrum of statistical procedures, the users of the high-throughput platforms are still facing the crucial challenge of deciding which test statistic is best adapted to the intrinsic properties of their own datasets. To meet this challenge, we recently introduced an adaptive procedure, named ROTS (Reproducibility-Optimized Test Statistic), which learns an optimal statistic directly from the given data, and whose relative benefits have previously been shown in comparison with state-ofthe-art procedures for detecting differential expression. Using gene expression microarray and mass-spectrometry (MS)-based protein expression datasets as case studies, we illustrate here the practical usage and advantages of ROTS toward detecting reliable marker lists in clinical transcriptomic and proteomic studies. In a public leukemia microarray dataset, the procedure could improve the sensitivity of the gene marker lists detected with high specificity. When applied to a recent LC-MS dataset, involving plasma samples from severe burn patients, the procedure could identify several peptide markers that remained undetected in the conventional analysis, thus demonstrating the effectiveness of ROTS also for global quantitative proteomic studies. To promote its widespread usage, we have made freely available efficient implementations of ROTS, which are easily accessible either as a stand-alone R-package or as integrated in the open-source data analysis software Chipster. Jukka Hiissa is a PhD student in the Biomathematics Research Group at the Department of Mathematics, University of Turku, Finland. His current research is focused on computational biology. Jarno Tuimala is a bioinformatician working at CSC-IT Center for Science, Espoo, Finland, providing centralized bioinformatics services for universities and develops the Chipster software for microarray data analysis. Aleksi Kallio is a computer scientist working at CSC-IT Center for Science, Espoo, Finland. He has specialised in distributed architectures for data mining applications and develops the Chipster software for microarray data analysis. Eija Korpelainen is a bioinformatician working at CSC-IT Center for Science, Espoo, Finland, providing centralized bioinformatics services for universities and develops the Chipster software for microarray data analysis.
INTRODUCTION
Stemming from the needs of genome-wide microarray studies, a number of statistical procedures has been developed for detecting differentially expressed genes across given sample classes, such as healthy and disease groups (for a comprehensive list of different approaches, we refer the reader to the excellent reviews [1] [2] [3] [4] [5] [6] ). While most of the early microarray studies used simple test statistics, such as fold-change or signal log-ratio, today's transcriptomic profiling experiments are exploiting the benefits of statistical hypothesis testing procedures, such as those based on modified t-tests, including SAM (Significance Analysis of Microarrays) [7] or LIMMA (Linear Models for Microarray Data) [8] . Although several of these methods have been made available to the experimental practitioners as software tools, and new ones are constantly being developed, only limited efforts have been devoted to provide the users of the high-throughput platforms with practical guidance on how to choose between the different analytical tools, or how to optimize their performance for a given dataset in real applications [9, 10] .
Although most statistical procedures can find consistent sets of differentially expressed genes when the sample sizes are relatively large, their performance can vary drastically depending on the type and amount of data under analysis. The relatively high cost of the genome-wide experiments and the scarcity of biological samples, such as clinical specimens, often results in studies performed on small sample sizes, which can impair the standard statistical tests of differential expression [11, 12] . In the presence of high inter-sample variation, which is frequently implicit especially in clinical materials, the profiling studies can therefore result in disease-related marker sets which share only a relatively small number of common genes across different studies and/or analysis procedures, or even between different sub-samples of the same study population [13] . The stability of the candidate genes is an important prerequisite for the success of the follow-up studies, involving, for instance, development of biomarkerbased classifiers for diagnostic and prognostic prediction [6, 14] , or clinical evaluation studies in much larger and well-controlled populations.
The practical challenges the researchers are still facing were exemplified by the recent debate over the recommendations from the MicroArray Quality Control Consortium (MAQC); the original study showed, by means of standardized protocols on human RNA samples, that reproducible gene lists can be obtained by using the simple fold-change as the primary ranking statistic, while the statistical significance of the findings was considered as a less important criterion [15] . This recommendation was called into question by Klebanov and colleagues, who showed a counter-example on a simulated dataset with a fixed number of genes, modelled as normally distributed random variables, in which the standard t-statistic showed superior performance over the fold-change in terms of statistical power and false discovery rate (FDR) [16] . These observations indicate that there is no universally best method, but the selection of a suitable test statistic depends upon the intrinsic properties of the data, such as the number of differentially and nondifferentially expressed genes and their distributional characteristics, as well as the number of biological samples available; while sometimes the fold-change or the standard t-statistic is optimal, in many cases a modified version of the t-statistic is preferable [17] .
To bypass the problem of using the same predefined test statistic in each study, we recently introduced a reproducibility optimization procedure, named ROTS, which provides a principled means to optimally adjust the test statistic to the properties of a given dataset [17] . In our previous work [17] , the relative benefits of ROTS were extensively demonstrated under various types of simulated conditions, as well as on the Affymetrix benchmark spike-in data, in comparison with a number of widely used statistical procedures, such as the LIMMA. We also compared its performance with those of two previously introduced data-adaptive procedures, SAMROC and DATS, which have shown to perform better than the popular SAM statistic [9, 10] . The performance of ROTS was further confirmed in a smaller-scale research setting, using real data from our unpublished cDNA microarray study, which involved the detection of differences between asthma patients and healthy controls [17] . These comparisons using various evaluation criteria, such as ROC analyses and marker genes, supported systematically the benefits of ROTS as compared to the alternative methods, and suggested the reproducibility optimization procedure as a general approach to select an optimal test statistic for any given dataset, without relying on a priori assumptions, such as functional annotations of the genes, which could bias the findings and their biological interpretation.
In the present work, we first briefly review the basic concepts of the data-adaptive test statistic, ROTS, and then give two concrete case studies that illustrate its practical advantages when applied to publicly available clinical materials. In the first case study on transcriptomic data, we demonstrate how the procedure can improve sensitivity of leukemia-related markers as compared to those detected with the two rivalling statistics, the foldchange and standard t-statistic, or with the LIMMA procedure (run with default settings in the Bioconductor 'limma' package). In the second case study on clinical proteomics material, we show that the procedure is not limited to detecting biomarkers in microarray studies only, but it can be applied to other large-scale profiling data as well. In particular, the recent advances in liquid chromatography-mass spectrometry (LC-MS)-based proteomic approaches are enabling quantitative and comparative profiling of complex peptide or protein mixtures in such sample sizes that are suitable for sound statistical evaluation [18] . Using a recent LC-MS dataset as an example [19] , we illustrate that the ROTS procedure is robust enough to cope with the many missing identifications and quantifications that typically occur in LC-MS datasets. Finally, we provide two user-friendly implementations of ROTS, which are freely available and easily accessible to the microarray and proteomics communities.
DATA-ADAPTIVE TEST STATISTICç ROTS
The underlying idea of the ROTS procedure is to select a ranking statistic for a given dataset by maximizing the reproducibility of the gene lists detected in random sub-samples while preserving the original sample groups [17] . Similarly as in the earlier work [10] , the reproducibility is defined as the average overlap between top-ranked genes or proteins across bootstrap re-samples (sampling with replacement). However, no fixed number of the top identifications needs to be specified, but the length of the top list (k) is optimized together with the other parameters of the test statistic (). Additional enhancements were obtained by taking into account also the behavior of the test statistics under the null hypothesis of random data distribution. Therefore, the ROTS procedure does not require any a priori knowledge about the properties of the data, such as the number of differentially expressed genes or their distributional characteristics, which are rarely known in practice, and could therefore, lead to biased identification results.
Although any functional form could be used, in principle, the current implementation of ROTS optimizes the reproducibility among a family of modified t-statistics:
Here, the numerator is the absolute difference between the average expression levels x i in the two groups i ¼ 1, 2, and the denominator is the regularized version of their pooled standard error s with parameters ¼ ð 1 , 2 Þ specifying the statistic. In case 2 ¼ 0, the statistic (1) is essentially the same as the signal log-ratio if logarithmic expression values are used, while setting 2 ¼ 1 gives the SAM-statistic with a regularization constant 1 , with the standard t-statistic being the special case
The optimal statistic is determined by maximizing the reproducibility Z-score
1 2 f0, 0:01, . . . , 5g, 2 2 f0, 1g, k 2 f1, 2, . . . , Gg. The reproducibility R k ðd Þ is defined as the average overlap of the k top-ranked genes or proteins over pairs of bootstrapped datasets, s k ðd Þ is the estimated standard deviation of the bootstrap distribution, R 0 k ðd Þ corresponds to the null reproducibility in randomized datasets (permuted over samples), and G is the total number of genes or proteins probed. The false discovery rate (FDR) for the optimized statistic is calculated by randomly permuting the sample labels. In addition, the optimized reproducibility value R and its Z-score can be used to investigate whether the data variability and sample size are sufficient for detecting true differential expression from background noise, since low reproducibility values typically indicate that no differentially expressed genes or proteins can be reliably detected [17] .
CASE STUDY 1çCLINICAL MICROARRAY DATASET
Over the past decade, gene expression microarray technology has been a popular choice to address clinical research questions on a global scale. However, genome-scale expression profiling of clinical sample material often results in datasets with high dimensionality and complexity. This can pose severe problems to the standard statistical procedures, and hence lead to disease markers with compromised reproducibility. Here, we highlight these challenges and further demonstrate the advantages of ROTS using different sized clinical datasets. In particular, we illustrate that the optimization of the reproducibility within a given sub-sample can also improve the reproducibility between distinct sub-samples and the complete material.
As an example material, we used a public genome-wide microarray study of acute lymphocytic leukemia (ALL) patients [20] . This material consists a total of 128 pretreatment leukemia samples from adult patients with newly diagnosed ALL. Phenotypic classification between T-cell and B-cell lineages was determined with conventional immunophenotypic analysis of cell surface markers, and three types of genotypic abnormalities in the B-cell lineage were confirmed with molecular diagnostic studies. In the original study, the differences across the various sample groups were assessed with the analysis of variance (ANOVA), which in the case of two sample groups reduces to the ordinary t-test. Here, for the illustrative purposes, we selected two clearly distinct sample groups to be compared: namely, the 32 T-cell lineage cases without evidence of known molecular rearrangements (labelled as T-NEG), and the 37 B-cell samples with confirmed genotypic abnormalities (B-BCR/ABL cases). All the samples were hybridized to the Affymetrix U95Av2 GeneChips, which contains 12 625 probe sets (referred to here as genes), and the expression data were then normalized with the RMA procedure [20] . This dataset does not contain any missing values.
To investigate the sensitivity and specificity of the detections obtained with ROTS at different sample sizes, in comparison to those of its two special cases (namely signal log-ratio and t-test), we calculated the overlap of statistically significant genes [12] . The popular LIMMA procedure was used as an example of a statistic outside the family (1). More specifically, we first defined the list of differentially expressed genes using all of the 32 and 37 samples in the two ALL groups with the four different ranking methods, and then calculated their average overlap with the genes deemed significant in varying-sized sub-samples (using group-preserving random sampling without replacement). Only those genes with the highest specificity were considered with each method (FDR < 0.001). It was observed that, while the positive predictive value of the detections (precision) was close to 100% with each of the methods, ROTS showed the best sensitivity (recall) systematically at each sample size level ( Figure 1A ). As expected, not only the recall but also the number of significant genes increased The dotted lines near zero correspond to the expected recall in random lists of the same sizes (i.e. the number of genes with FDR < 0.001 in the particular sample divided by the total number of genes). All the data points are averages over 100 random sub-samples. The differences in recall between the methods were significant at each sample size level (paired t-test, P < 10
À6
). (B) The length of the gene lists (y-axis) detected with the four methods as a function of the sample size (x-axis). The dots on the right (column All) show the number of significant genes identified when using the complete material (32 and 37 samples in the T-NEG and B-BCR/ABL groups, respectively), while the remaining columns correspond to the average number of the genes deemed significant in the different-sized sub-samples. The genes with FDR < 0.001 were considered significant with each method.
when the sample size was increased with each method ( Figure 1B) . However, the optimized ROTS parameters effectively adapted to the changing properties of the datasets, and also revealed higher reproducibility with larger sample sizes ( Table 1, panel A) .
This case study illustrates that ROTS can provide reliable detections even in the presence of confounding factors, such as large inter-individual variability, known to occur in clinical microarray studies. Besides further confirming the advantages gained by using the ROTS procedure, these results also support the recent observation that, when a relatively stringent FDR-threshold is used, the detected lists comprise mostly true findings only, even with smaller sample sizes [12] .
CASE STUDY 2çCLINICAL LC-MS DATASET
The recent advances in the LC-MS-based technologies are enabling new large-scale proteomic applications, such as peptide biomarker discovery in clinical materials. Despite its tremendous potential, the development and application of the technology is still in its emerging stage, often resulting in datasets with compromised accuracy and coverage. In particular, the existence of many missing peptide identifications and quantifications due to various experimental reasons still remains a frequent problem in large-scale clinical studies. If a complete data matrix with no missing values is required, as is the case for many analysis tools, considerable amounts of protein information will be lost for biomarker discovery.
To illustrate these challenges, we used one of the first publicly available large-sized LC-MS datasets which involves human plasma samples from 18 severe burn patients [19] . When using immunoaffinity depletion and cysteinyl-peptide enrichmentbased fractionation, combined with high resolution LC-MS measurements, a total of 312 plasma proteins were confidently identified and quantified with a minimum of two unique peptides per protein.
Similarly as in the original work, the samples were divided into the groups of nine male and nine female patients purely for the illustrative purpose. The original study used signal log-ratios to assess the relative protein abundance differences between the two groups of patients, and indicated the missing abundance data across the samples as the main problem for the comparative analyses [19] . To avoid the need of a priori mapping of the peptides to unique proteins and their summarization into protein-level abundance changes, which may miss, for instance, the detection of isoform-specific changes, we focused here on peptide-level detections, which can subsequently be linked to the corresponding proteins [21, 22] . This also ensured that the data contained a reasonable number of features for the illustrative purpose. Here, we used the relative abundance ratios for the 2341 peptides obtained with the 18 O-reference based isotope labelling approach, since these gave better quantitative precision compared to label-free approach [19] . Protein abundance data can similarly be used in place of the peptidelevel data.
To investigate whether ROTS is applicable to also deal with incomplete information, we modified the procedure so that it effectively ignores the missing values when comparing the sample groups in the reproducibility optimization of the statistic (1), and tested the modified version in the LC-MS dataset. More specifically, the peptides of the original LC-MS dataset were divided into a series of overlapping subsets with missing value rates ranging from 0 to 15% by requiring that at most 0-5 missing values can occur out of the 9 patient samples per group. Interestingly, the optimized statistic (1) at each missing value rate was equal to the standard t-test ( 1 ¼ 0, 2 ¼ 1; Table 1 , panel B). This suggested that the peptide abundances in these data were more or less normally distributed, which was also supported by the normality test of the LC-MS data, compared to that of the microarray data (Shapiro-Wilk test; Table 1 ). The new peptide detections made when allowing an increasing number of missing values were, on average, more significant than those that were lost ( Table 2 , panel A). Moreover, even if a rather moderate significance level was used (FDR < 0.1), the signal-log ratio could identify only the few most clear-cut peptide markers, while it missed the more subtle differences in the abundance levels that can occur between the two sample groups (Table 2, panel B). We also tested the applicability of LIMMA to the LC-MS dataset since its implementation allows for missing values. However, this treatment of missing values only detected a single significant peptide (FDR ¼ 0.10) throughout all the comparisons considered here.
An example of a candidate marker that was missed with the signal log-ratio but detected with ROTS is the peptide LEDMEQALSPSVFK (IPI00291866.3), which corresponds to the plasma protease C1 inhibitor protein. According to ROTS, it shows significantly higher abundance ratios in female than in male patients ( Figure 2A) . Notably, also several other peptides of this protein were among the top detections with ROTS, whereas none of them was detected with the signal log-ratio ( Figure 2B ). The potential biological relevance of the finding was supported by the literature; C1 inhibitor has been shown to reduce neutrophil activation in patients with sepsis [23] , while greater increase in neutrophil activation has been observed in male rats than in female rats after burn injury [24] .
This case study illustrates that the ROTS procedure is relatively robust not only against the high inter-individual and technical variability, but also against frequent missing peptide quantifications, The rows indicate the different missing value thresholds, i.e. the maximum number of missing peptide quantifications allowed per sample group (0^5). False discovery rate (FDR) of those peptides that were found significant with the present missing value threshold but not with the preceding threshold.
c FDR of those peptides that were found significant with the preceding missing value threshold but not with the present threshold. Since we considered a peptide-level analysis, duplicate peptides that associate with distinct plasma proteins were detected.
which are characteristic to the large-scale quantitative proteomic studies. These results also support the earlier observation that the simple signal log-ratio statistic can lead to spurious and limited peptide biomarker findings in clinical LC-MS studies with frequent missing values [19] .
IMPLEMENTATIONS AND INSTRUCTIONS FOR USAGE
The implementation of ROTS is distributed in two forms: as a stand-alone R-package and as integrated into the open-source Chipster software. The standalone R-package takes the pre-processed gene expression or protein abundance data matrix as its input, and outputs the optimized ROTS-parameters along with the resulting gene or protein rankings and their FDRs. These data can then be further analyzed with the tools of choice of the researcher in R or using other analysis software. R-packages for Linux, Windows and MAC OS X are freely available under the terms of the GNU General Public License version 2 or newer from our website (http:// www.math.utu.fi/short/rots.html), which also provides further documentation of these packages and their installation instructions. An example use case of the ROTS R-package in the Affymetrix spike-in data is demonstrated in Figure 3 . The running time with this dataset, consisting of 24 samples and 12 626 genes, is less than 10 min on a standard PC (2.20 GHz, 2 GB RAM), and the computational complexity scales up to allow efficient application of ROTS to much larger datasets as well. Second, the ROTS procedure has been integrated in the open-source software package Chipster (manuscript in preparation). Chipster is a versatile platform for microarray data analysis with Bioconductor and other tools. Chipster is used through an intuitive graphical user interface that connects to a server environment for performing the computational work. This implementation allows users without programming skills or resources an easy access to ROTS. All the advanced preprocessing, missing value estimation, clustering and visualization options of Chipster are also directly available. Even if Chipster is currently used mainly for microarray data analysis, it is a generic platform allowing easy implementation of analysis functionality also for other types of data, such as the LC-MS data demonstrated here. Chipster is freely available under the GPL open source license at the SourceForge website (http://chipster.sourceforge .net/). For evaluation purposes, guest accounts are available for the Chipster running on the CSC's server (http://chipster.csc.fi). An example use case of ROTS in Chipster is provided as a supplementary file, which contains an example Chipster session of the LC-MS data analysis that can be directly downloaded into Chipster.
CONCLUSION
The present results demonstrate that the ROTS procedure enables the user to optimally adjust the test statistic for the properties of a given dataset. Applications to the clinical transcriptomic and quantitative proteomic datasets with notably different characteristics and sample sizes confirmed its advantages and potential to provide reliable molecular markers, many of which would have been missed with standard data analysis procedures. The optimized reproducibility guarantees that ROTS is able to reliably distinguish those key markers, which are directly linked to the phenotypespecific expression variability, from the confounding elements whose expression has been altered by secondary effects (e.g. biological variability) or technical artifacts (e.g. missing values). However, if the confounding variation greatly exceeds the actual phenotypic variation, then such materials can be beyond the capacity of the current statistical procedures, including ROTS, which rely on the assumption that the groups being compared are relatively homogeneous. Development of improved procedures for such cases is likely to be of significant practical importance in the near future as the clinical profiling datasets are constantly increasing both in their size and complexity.
Key Points
The reliability of the markers identified in global profiling studies depends on the test statistic as well as on the type and amount of data under analysis. Signal log-ratio or fold-change statistics can identify only the most drastic changes, but they often miss the more subtle between-group differences.
Modified t-statistics are preferred over the signal log-ratio, provided a sufficient number of biological replicates are available in the sample groups. The ROTS procedure can efficiently select an optimal test statistic for a given dataset, and it is robust against moderate degrees of missing data values.
# The Affymetrix spike-in data and the class labels. 1 1 1 1 1 1 1 1 1 The function summary can be used to print a summary of this information and to select a user-specified number of top candidates or candidates at a specified FDR-level.
